相关实验视频

Updated: May 15, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

目标 DKK3 改造瘤免疫微环境并增强癌症免疫疗法

Kai Shi¹, Yan Zhao¹, Hao Ye¹

¹Department of Thoracic Surgery, Huai'an Hospital of Huai'an City & Huai'an Cancer Hospital & The Affiliated Huai'an Hospital of Jiangsu College of Nursing, Huai'an, Jiangsu Province, China.

|April 9, 2025

概括

迪克科夫-3 (DKK3) 是一种新的目标,可以抑制抗瘤免疫力. 阻断DKK3可增强T细胞的反应并改善存活率,为癌症免疫治疗提供了一种新的策略.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

免疫检查点阻塞 (ICB) 疗法在癌症治疗中表现有前途,但患者受益有限,需要新的治疗点.
瘤免疫微环境 (TIME) 通常会抑制抗癌免疫反应,阻碍免疫疗法的有效性.

研究的目的:

确定和描述Dickkopf-3 (DKK3) 作为癌症的新型免疫治疗点.
调查DKK3在调节抗瘤免疫力和TIME中的作用.

主要方法:

对人类癌症类型中DKK3表达的分析以及与生存率的相关性.
对DKK3对CD8+T细胞激活和CD4+T细胞分化影响的实体评估.
使用四种小鼠癌症模型进行体内研究,以评估DKK3阻断的有效性.
在DKK3封锁后对TIME调制的评估.
使用DKK3和PD-1阻断的组合疗法研究.

主要成果:

在各种癌症中,DKK3的表达上调,并与较差的存活率有关.
DKK3 抑制了 CD8+ T 细胞的激活和 Th1 的分化.
DKK3阻塞在小鼠模型中显示出显著的抗瘤作用和改善生存率.
DKK3封锁通过增加CD8+T细胞和Th1透,同时减少M2巨细胞和MDSCs来重塑TIME.
联合DKK3和PD-1封锁产生了协同作用的抗瘤效应.

结论:

在时间内,DKK3在抑制抗瘤免疫力方面发挥着关键作用.
DKK3封锁是提高癌症免疫疗法的有效性的一种有希望的策略.
针对DKK3,可能与PD-1阻断等现有疗法结合,可以改善患者的治疗结果.

关键词:

癌症免疫疗法癌症免疫疗法 DKK3 DKK3 DKK3 DKK3 DKK3 DKK3 DKK3 DKK3 DKK3 DKK3 在PD-1封锁中.一个T细胞细胞.瘤的免疫微环境

更多相关视频

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...